MISSISSAUGA, ON, April 5, 2018 /CNW/ - TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol), has been approved in Canada as the first and only inhaler ...
Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio Upfront payment of US$15m Up to US$80m of development milestone payments Mid teen percentage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback